The infectivity and replication of human (HIV-1), feline (FIV), and murine 
ABSTRACT
The infectivity and replication of human (HIV-1), feline (FIV), and murine (LP-BM5) immunodeficiency viruses are all inhibited by several nucleoside analogues after intracellular conversion to their triphosphorylated derivatives. At the cellular level, the main problems in the use of these drugs concern their limited phosphorylation in some cells (e.g., macrophages) and the cytotoxic side effects of nucleoside analogue triphosphates. To overcome these limitations a new nucleoside analogue homodinucleotide, di(thymidine-3 '-azido-2 ',3 '-dideoxy-D-riboside)-5'-5'-pl-p2-pyrophosphate (AZTp2AZT), was designed and synthesized. AZTp2AZT was a poor in vitro inhibitor of HIV reverse transcriptase, although it showed antiviral and cytotoxic activities comparable to those of the parent AZT when added to cultures of a HTLV-1 transformed cell line. AZTp2AZT encapsulated into erythrocytes was remarkably stable. Induction of erythrocyte-membrane protein clusterization and subsequent phagocytosis of AZTp2AZT-loaded cells allowed the targeted delivery of this impermeant drug to macrophages where its metabolic activation occurs. The addition of AZTp2AZT-loaded erythrocytes to human, feline, and murine macrophages afforded almost complete in vitro protection of these cells from infection by HIVBa.L, FIV, and LP-BM5, respectively. Therefore, AZTp2AZT, unlike the membranediffusing azidothymidine, acts as a very efficient antiretroviral prodrug following selective targeting to macrophages by means of loaded erythrocytes.
Mononuclear phagocytes are important target cells for human immunodeficiency virus type 1 (HIV-1) infectivity and propagation in most tissues (1) (2) (3) (4) (5) (6) . Furthermore, because cytopathic effects on these cells are minimal, they serve as major reservoirs of HIV-1 with an important role in the pathogenesis of AIDS.
To be pharmacologically active, most antiviral nucleoside analogues [3'-azido-3'-deoxythymidine (AZT), ddC, etc.] must first be phosphorylated by cellular kinases (7, 8) . The activity levels of these enzymes depend on the cell type and the cell activation state (9, 10) . Usually, quiescent cells have low levels of the enzymes responsible for nucleoside analogue phosphorylation, while activation (e.g., mitogen stimulation) results in increased activity levels. Macrophages phosphorylate AZT and ddC at a much lower rate than peripheral blood mononuclear cells (11, 12 (14) . Using this drugdelivery system we have shown that erythrocyte-encapsulated ddCTP protects in vitro human macrophages from HIV-1 infectivity and both in vitro and in vivo murine and feline macrophages from the infectivity of the murine immunodeficiency virus LP-BM5 and feline immunodeficiency virus (FIV), respectively (14) (15) (16) . Furthermore, the anti-retroviral activity of erythrocyte (RBC)-resealed ddCTP always exceeded that of the nonphosphorylated nucleoside analogue (17) .
In the past few years it has been shown that the nucleotide analogues are responsible in the cell for antiviral activity and cell toxicity (18, 19 (23) . AZT-MP tri-n-octylammonium salt was prepared by dissolving 0.25 mmol of AZT-MP-free acid (100 mg) in 3.0 ml of methanol and 0.45 ml of tri-n-octylamine.
The mixture was stirred for 30 min at 25°C and vacuum dried.
The residue was suspended in 2 ml of N,N-dimethylformamide and dried under reduced pressure. The latter procedure was repeated three times.
Pl-AZT-5'-P2-diphenyl pyrophosphate (0.25 mmol) was then dissolved in 1.8 ml of anhydrous pyridine and added to 0.25 mmol of the AZT-MP tri-n-octylammonium salt, prepared as above, together with 0.32 ml of hexamethylphosphotriamide. The mixture was dried under reduced pressure; 0.4 ml of anhydrous pyridine was added to the residue and the resulting solution was stirred for 24 h at 25°C and then vacuum dried. The residue was suspended in 6 ml of H20, the pH was adjusted to 8.0 with 1M NaOH, and the mixture was extracted three times with 6 (14) . The AZTp2AZT-loaded RBC were then modified to increase their recognition by macrophages. The procedure is described in detail elsewhere (14) . The number of IgG bound per cell and phagocytosis of drug-loaded RBC was determined in vitro as described (14) .
We also evaluated the amount of AZTp2AZT delivered by carrier RBC to macrophages and its stability in macrophages. 40 cycles of denaturation at 94°C for 1 min, annealing at 50°C for 1 min, and extension at 72°C for 2 min followed by final extension at 72°C for 15 min. A 10-,l aliquot of this amplified mixture was reamplified with the second pair of primers using exactly the same conditions. The PCR products were analyzed by electrophoresis on 1.5% agarose gel, transferred to a nylon membrane, and hybridized with 498 bp of the p24 gag gene probe cloned in a TA-cloning plasmid (Invitrogen). As an internal control the feline hexokinase gene was amplified with the following primers: 5'-ACATGGAGTGGGGGGCCTTTGG-3' (sense) corresponding to nucleotides 2198-2219 and 5'-GTTGCGGAC-GATTTCACCCAGG-3' (antisense) corresponding to nucleotides 2328-2349 in the human hexokinase type I cDNA.
Detection was performed with a feline hexokinase probe.
Labeling of the DNA probes was by random primer DNAlabeling kit from Bio-Rad.
Murine macrophages were obtained from the peritoneal cavity of C57BL/6 mice and cultured as described above. AZTp2AZT-loaded RBC and infection were as described for FIV with the following modifications: the LP-BM5 was prepared as a cell-free supernatant from SC-1 cells according to standard procedures (20) . The amplification of defective virus genome (BM5d) was performed as reported elsewhere (17 (14) . The features of this process are reported in Table 1 , which shows that a concentration of 3 + 0.3 pmol of AZTp2AZT per 106 macrophage cells was eventually obtained by using loaded RBC containing 0.4 ± 0.03 g/mol of AZTp2AZT per ml. In macrophages, AZTp2AZT showed a progressive decay until becoming undetectable after 3 days since onset of phagocytosis of the loaded RBC (Fig. 2) .
These data are consistent for metabolism of AZTp2AZT taking place largely in macrophages rather than in the carrier RBC, thus fulfilling a major requirement of the newly synthesized molecule.
Comparable results in terms of AZTp2AZT stability in the carrier red cells and in the macrophages were obtained with both murine and feline homologous systems (not shown). Thus, for instance, >90% of AZTp2AZT was found after incubating the loaded murine and feline RBC for 24 h at 37°C. Following uptake of the AZTp2AZT-loaded homologous RBC by the murine and feline macrophages, the decay of AZTp2AZT takes 3 days to be completed. Antiviral Activity of AZTp2AZT-Loaded RBC. Human monocyte-derived macrophages were cultured for 10 days and then treated with AZTp2AZT-loaded RBC, unloaded RBC, or 0.1 ,uM AZT in culture medium for 20 h. All cell cultures were then washed with new medium and infected with a macrophage-tropic strain HIV-lBa-L. HIV-1 proviral DNA content and p24 production after 1 week were then determined. As shown in Fig. 3 , the AZTp2AZT-loaded RBC inhibited HIV-1 proviral formation by 93-97% (Fig. 3A , range of three experiments) and p24 production by 80% (Fig. 3B) . AZT at 0.1 ,uM in culture medium for 20 h had no effect on viral infectivity and production, while AZT at 0.1 /LM maintained in culture medium 
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